- Breaking News San Mateo County ninth-graders struggle to stay fit
- Breaking News Food and wine events
- Breaking News Ask Amy: What To Do When the Doctor Isn t in the House
- Breaking News Ed Blonz: Keep your diet normal pre-surgery
Stocks to Watch - DVAX, VSAT, ISIS, LLY.
0 Comments | M2 Presswire, December, 2006
M2 PRESSWIRE-11 December 2006-SmallCapReview: Stocks to Watch - DVAX, VSAT, ISIS, LLY(C)1994-2006 M2 COMMUNICATIONS LTD RDATE:11122006 Dynavax Technologies (Nasdaq: DVAX) Closed at $9.54. Announced preliminary data from an ongoing open label Phase 2a study of the company's TLR9 agonist used in combination with rituximab as a treatment for patients with non-Hodgkin's lymphoma.
The study enrolled 23 follicular lymphoma patients who had relapsed after at least one prior treatment. Patients were evaluated using functional assays, gene expression profiling and immunohistochemistry studies. Dr. Friedberg indicated that patients treated with the TLR9 agonist who had clearly increased expression of TLR9 agonist- and interferon-inducible genes showed a prolonged...
- Getting to the root of beautiful hair: shiny, silky hair begins with a healthy scalp - includes list of resources and a recipe for an herbal scalp tonic
- Portfolio forecasting tools: what you need to know
- Made from scratch: When Honda built a plant in Alabama it also built a workforce-using local workers who had no experience in making cars - Recruitment & Hiring
- Beating the capital budgeting blues: developing capital request evaluation criteria - Financial Manager's Notebook - Column
- A multi-class SVM classifier utilizing binary decision tree
- Taylor Fund L.P. Gains 40.53% in Third Quarter
- SAS #82: sword or shield?
- Personality and organizational citizenship behavior